Patients with glycogen storage disease type Ib (GSD‐Ib), who suffer from chronic neutropenia and neutrophil dysfunction due to a buildup of 1,5‐anhydroglucitol‐6‐phosphate, have been successfully treated with SGLT‐2 inhibitors. This evidence concerns the gene SLC5A2 and glycogen storage disease Ib.